CHR d'Orleans
- Address
- 14 Hôpital avenue, 45067 Orléans, France
Male Urogenital Diseases
At CHR d'Orleans investigators are studying castration‑resistant prostate cancer and testing whether common cardiovascular drugs can extend patient overall survival. The work aims to improve treatment options for advanced prostate disease.
- Evaluation of aspirin and atorvastatin as adjunct therapy
- Long‑term survival outcomes in advanced prostate cancer
The site hosts three investigators and contributes two active trials to the European oncology network.
Neoplasms
Researchers at the Orléans center are conducting a study on metastatic grade 3 poorly differentiated neuroendocrine carcinoma of the gastro‑entero‑pancreatic system, comparing two chemotherapy approaches to improve progression‑free survival using RECIST v1.1 criteria. This effort seeks to identify the most effective first‑line regimen for this aggressive cancer type.
- Comparison of mFOLFIRINOX versus platinum‑etoposide
- Optimization of first‑line chemotherapy protocols
The trial is part of a broader initiative to enhance therapeutic strategies for rare neuroendocrine tumors across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHR d'Orleans
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparison of mFOLFIRINOX Versus Platinum-Etoposide in First-Line Chemotherapy for Metastatic Grade 3 Gastroenteropancreatic Neuroendocrine Carcinoma | Centre Hospitalier Universitaire De Dijon | Phase II | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2019-06-26 | 2019-06-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.